nasopharyngitis


Also found in: Dictionary, Thesaurus, Encyclopedia.

nasopharyngitis

 [na″zo-far″in-ji´tis]
inflammation of the nasopharynx.

nasopharyngitis

/na·so·phar·yn·gi·tis/ (-far″in-ji´tis) inflammation of the nasopharynx.

nasopharyngitis

Infectious disease Acute nasopharyngeal inflammation, often with keratoconjunctivitis; both occur in common cold and are attributed to viruses. see Common cold.

nasopharyngitis

inflammation of the nasopharynx.
References in periodicals archive ?
A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
ADVERSE REACTIONS The most common adverse reactions with STIOLTO (>3% incidence and higher than any of the comparators -- tiotropium and/or olodaterol) were: nasopharyngitis, 12.
The most common adverse reactions observed in clinical trials (frequency greater than or equal to 10 percent of patients) were pyrexia, headache, cough, nasopharyngitis, vomiting, arthralgia, and limb injury.
Common adverse events included headache, nasopharyngitis, and upper respiratory tract infection.
Headache and nasopharyngitis were the most frequently reported adverse events across treatment groups with no notable changes in any cardiovascular parameters measured by 24 hour ambulatory blood pressure, clinical chemistry, hematology, or ECG parameters.
The most common side effects reported by people using Striverdi Respimat in the clinical study were nasopharyngitis (runny nose), upper respiratory tract infection, bronchitis, cough, urinary tract infection, dizziness, rash, diarrhea, back pain and arthralgia (joint pain).
The most commonly reported (>=5% of patients) TEAEs in patients taking Concerta included decreased appetite, headache, insomnia, irritability, weight decreased, dizziness, nausea, and nasopharyngitis.
The linagliptin adverse reactions label notes that side effects reported in more than 5% or more patients treated with the drug include nasopharyngitis and that hypoglycemia was more commonly reported in patients treated with linagliptin and sulfonylurea compared with placebo and sulfonylurea.
The most commonly reported TEAEs in patients taking Vyvanse (reported in 5% or more of patients) included dry mouth, headache, insomnia, upper respiratory tract infection, nasopharyngitis, constipation, nausea, decreased appetite, irritability, bruxism, sinusitis, anxiety and feeling jittery.
1 letters from baseline, compared to a loss of 2 letters in patients receiving sham injections (p5%, and which have a higher incidence than sham, include nasopharyngitis, conjunctival hemorrhage, dry eye, eye pain, nausea, dizziness, headache.